Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2023-04-20 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement from Shanghai SAILUN Biotech Co., Ltd. regarding the revision of the company's Articles of Association (公司章程). It details specific amendments to the company's governance documents, referencing relevant laws and regulations such as the Company Law, Securities Law, and listing rules. The content focuses on corporate governance structure, shareholder meeting procedures, board responsibilities, and other internal governance matters. There is no financial data, earnings information, or audit content. The document is not a report itself but an official announcement of changes to governance documents. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed governance content, supporting a high confidence classification.
2023-04-20 Chinese
赛伦生物：独立董事对公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees during the reporting period (2022-01-01 to 2022-12-31). It references regulatory requirements from the China Securities Regulatory Commission and discusses compliance and risk control related to external guarantees. The document is short (451 characters) and focuses on a specific regulatory disclosure rather than a full audit or annual report. It does not contain financial statements or detailed audit results but is a regulatory compliance disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and attestation documents that do not fit other categories.
2023-04-20 Chinese
赛伦生物：关于召开2022年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2022 Annual General Meeting (AGM) of Shanghai SAILUN Biotechnology Co., Ltd., including details such as the date, voting methods, meeting agenda, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather the announcement and logistical information for the AGM. The document length is 3601 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2023-04-20 Chinese
赛伦生物：2022年年度报告
Annual Report Classification · 100% confidence The document is titled "2022 年年度报告" which translates to "2022 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes signatures from the legal representative and accounting officers, and an unqualified audit opinion from the accounting firm. The content covers comprehensive financial performance, business operations, market conditions, and future outlook, which are typical components of an Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a certification document. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-04-20 Chinese
赛伦生物：关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai SAILUN Biotech Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory committee approvals, the amount and purpose of the cash management, risk disclosures, and independent opinions. The document references regulatory guidelines and approvals related to the use of raised funds but does not contain financial statements or detailed financial performance data. The length is 4167 characters, which is relatively short and the content is focused on an announcement of a financing-related activity rather than a full financial report. Therefore, it is best classified as a Capital/Financing Update (CAP) rather than an Annual Report, Interim Report, or Regulatory Filing. It is not a report publication announcement since it contains substantive information about the cash management plan and approvals.
2023-03-22 Chinese
赛伦生物：独立董事关于第三届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting agenda item about the use of temporarily idle raised funds for cash management. It references compliance with company law, company articles, and regulatory guidelines. The content is a formal opinion on a board resolution rather than a full report or financial statement. The document length is short (729 characters), and it does not contain financial statements or detailed financial data. It is not an announcement of voting results but an independent opinion related to board matters. This fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management opinions.
2023-03-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.